News | January 24, 2025
Alivus Life Sciences delivers 12% revenue growth
EBITDA margins expand to 31.3%
EBITDA margins expand to 31.3%
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
PAT after MI is Rs. 41 crore which is 162% increase
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
The Emcure Research Centre (ERC) will drive research across multiple dosage forms, including OSD, injectables, novel drug delivery systems (NDDS), inhalers and topical and transdermal formulations
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
The company plans to fund this Capex through debt and internal accruals and expects the project to be completed by FY27
According to IQVIATM sales data for the 12-month period ending November 2024, the Vitamin K1 Injectable Emulsion USP, 10 mg/mL market achieved annual sales of approximately $19.7 million
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
